With over 250 employees, the Brazilian unit is the
fourth largest of the group and demonstrates quality for
other subsidiaries. In its portfolio, Zambon Brazil has
a line of products with more than 30 items, including
succesful drugs such as Fluimucil and Monuril Spidufen.
“
When Zambon looks, as a corporation, for potential
growth, Brazil is the first country to be considered. We
have grown on average 12 percent annually over the
past four years. The Brazilian unit is probably looking to
be the second largest in the Group in the next two years
And if we look at the market, it surely has the greatest
potential at this time. Our sales volume is almost double
compared to that of Russia and almost five times in
comparison with China,” says Borges.
Borges also notes that the company’s growth in
the country took place following the development of a
strategy aligned with company size. “We do not seek
to replicate the strategy that other big companies have.
We identify the best strategies for Zambon, looking at
our culture, our portfolio, our ambitions,” says Borges.
Zambon Group
Visit us online at
